Back HIV Treatment Search for a Cure

Search for a Cure

AIDS 2014: Romidepsin Activates Latent HIV, But Does Not Decrease Viral Reservoir

The HDAC inhibitor romidepsin was able to awaken latent HIV in resting T-cells, causing it to start producing new virus, but this was not associated with a decrease in the size of the viral reservoir in T-cells, researchers reported at the 20th International AIDS Conference this week in Melbourne. This finding suggests that kicking HIV out of hiding will not be adequate for a functional cure without strengthening immune response against the virus.

alt

Read more:

TAG Releases 2014 HIV, Hepatitis C, and Tuberculosis Pipeline Report

The Treatment Action Group (TAG) and HIV i-Base this week released the latest edition of their annual Pipeline Report, covering new therapies and related technologies for HIV, hepatitis C, and tuberculosis (TB), in conjunction with the 20th International AIDS Conference taking place this week in Melbourne, Australia.

alt

Read more:

HIV Detected in Mississippi Baby Who Appeared Cured

A child in Mississippi who had undetectable HIV viral load for more than 2 years off antiretroviral treatment and was heralded as a rare case of "functional cure" has been found to still be infected with the virus, researchers announced this week, tempering optimism about one cure research approach.

alt

Read more:

AIDS 2014: Researchers Discuss Progress Towards an HIV Cure [VIDEO]

Progress along the multi-pronged path towards a cure for HIV was one of the themes at the 20th International AIDS Conference (AIDS 2014), taking place this week in Melbourne. Researchers provided updates on the "Mississippi Baby," a novel assay for detecting low levels of hidden virus in the body, and using the anti-cancer drug romidepsin to reactivate latent virus.

alt

Read more:

Studies Explore Viral Reactivation Strategies for Potential HIV Cure

Compounds that increase random fluctuations or "noise" in HIV gene expression can help trigger reactivation of latent HIV in immune cells, one of the key barriers to a cure, researchers reported in the June 20 edition of Science. A related study identified another type of agent -- Ingenol B, derived from an Amazonian plant -- that reactivates latent HIV reservoirs, but another study found that one type of latency releaser may facilitate infection of CD4 cells.

alt

Read more: